Blogs

Biotech and the Election: This election will be the food movement’s moment of truth, says Michael Pollan

Biotechnology was supposed to trigger a food revolution: Higher crop yields and the end of world hunger

"This election will be the food movement’s moment of truth, says Michael Pollan" 

 

Biotechnology was supposed to trigger a food revolution: Higher crop yields and the end of world hunger. Or so promised once-chemical producer Monsanto, now the mother of all agricultural biotechnology companies. But 20 years on, conventional methods of breeding have actually done more to lift crop yield than genetically modified crops ever have, says food journalist, author, and professor Michael Pollan.

An Apple a Day Keeps Cholesterol at Bay

Study shows an apple a day keeps cholesterol down

Eating an apple a day might in fact help keeps the cardiologist away, new research suggests. In a study of healthy, middle-aged adults, consumption of one apple a day for four weeks lowered by 40 percent blood levels of a substance linked to hardening of the arteries. Taking capsules containing polyphenols, a type of antioxidant found in apples had a similar, but not as large, effect. 

 Source Article:

Heart Drug Eases Pain of Rare Disease

An older medication originally approved to treat heart problems eases pain and stiffness from a very rare muscle disease

An older medication originally approved to treat heart problems eases pain and stiffness from a very rare muscle disease, a new study reports. The findings are good news not only for the relatively small number of people around the world estimated to have the disease—nondystrophic myotonia—but also for many other patients who have one of the thousands of other diseases that are very rare, neurologists say.

Celegen Corporation's Revlimid Combo Fails as Prostate Cancer Therapy

Adding lenalidomide (Revlimid) to the chemotherapy regimen led to greater toxicity and worse survival in patients

Celegen Corporation's Revlimid Combo Fails as Prostate Cancer Therapy Adding lenalidomide (Revlimid) to the chemotherapy regimen led to greater toxicity and worse survival in patients with untreated castration-resistant prostate cancer (CRPC), results of a large international trial showed. Men randomized to a regimen of lenalidomide, docetaxel, and prednisone, had a 53% increased mortality hazard, a 32% greater hazard for progression, and significantly higher rates of neutropenia, febrile neutropenia, and multiple non-hematologic adverse events.

Pages